Date: 2014-08-22
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 29th Annual International Papillomavirus Conference
Company: Hera Therapeutics (USA - CA)
Product: HTI-1968
Action mechanism:
Disease: human papillomavirus infection
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On August 22, 2014, the researchers Louise T. Chow, Ph.D. and Thomas Broker, Ph.D have presented results showing that HTI-1968, a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer. When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow\'s work at the University of Alabama, Birmingham. Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.
